| ADOC Stock | | | EUR 8.19 0.78 8.70% |
CEO
Dr. Olivier Soula has served as Vice President Research Development Deputy Chief Executive Officer and Member of the Board of Directors at Adocia SA since December 19. 2012. He is graduate of ENSIC and he holds a Ph.D. in polymer science and an MBA from IAE, Lyon. He worked for eight years at Flamel Technologies as Director of the Nanotechnologies department. He was in charge of a team dedicated to the innovation of protein delivery systems, in partnerships with pharmaceutical companies. He was also responsible for the development and the implementation of the IT System. He is coauthor of 31 patents relating to protein delivery. since 2012.
| Age | 47 |
| Tenure | 12 years |
| Professional Marks | MBA |
| Phone | (33) 04 72 36 39 67 |
| Web | www.adocia.com |
Adocia Management Efficiency
The company has return on total asset
(ROA) of
(0.245) % which means that it has lost $0.245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(3.6138) %, meaning that it generated substantial loss on money invested by shareholders. Adocia's management efficiency ratios could be used to measure how well Adocia manages its routine affairs as well as how well it operates its assets and liabilities.
Adocia has accumulated 18.29
M in total debt with debt to equity ratio
(D/E) of 4.45, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Adocia has a current ratio of 3.33, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Adocia until it has trouble settling it off, either with new capital or with free cash flow. So, Adocia's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Adocia sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Adocia to invest in growth at high rates of return. When we think about Adocia's use of debt, we should always consider it together with cash and equity.
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Adocia SA was founded in 2005 and is headquartered in Lyon, France. ADOCIA operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 116 people. Adocia (ADOC) is traded on Euronext Paris in France and employs 110 people.
Management Performance
Adocia Leadership Team
Elected by the shareholders, the Adocia's board of directors comprises two types of representatives: Adocia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adocia. The board's role is to monitor Adocia's management team and ensure that shareholders' interests are well served. Adocia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adocia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dominique Takizawa, Independent Member of the Board | |
| Jose Correia, Head of the Preclinical and Clinical Department, HSQE Manager and Project Manager | |
| Valerie Danaguezian, Chief Financial Officer, Administrative Director | |
| Ekaterina Smirnyagina, Independent Director | |
| Laurent Arthaud, Director Representative of Bpifrance Investissement | |
| Remi Soula, Co-Founder, Director of Bus. Devel. and Intellectual Property and Scientific Advisor | |
| Valrie Danaguezian, CFO Director | |
| Martin Gaudier, Head of Biology Department | |
| Olivier Soula, Deputy Chief Executive Officer, Vice President - Research & Development, Director | |
| David Duracher, Head of Pharmaceutical Development and Physical Chemistry Departments | |
| Gregory Meiffren, Head of Biology Department | |
| YouPing Chan, Scientific Director | |
| Grard Soula, Chairman, CoFounder | |
| Geraldine Soula, Director of Development and Human Resources | |
| Olivier MBA, Deputy CoFounder | |
| Stanislav Glezer, Medical Doctor | |
| Grgory Meiffren, Head Mang | |
| Sarah Gould, Director of the Preclinical Department | |
| Olivier Martinez, Member of the Board | |
| Gerard Soula, Chairman of the Board, Chief Executive Officer | |
| Bertrand Alluis, Head of Analysis Department and Project Manager | |
| Richard Charvet, Head of Chemistry Department | |
Adocia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adocia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Adocia Stock
Adocia financial ratios help investors to determine whether Adocia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Adocia with respect to the benefits of owning Adocia security.